Anti-VEGF use for ROP is expanding beyond bevacizumab and ranibizumab, with aflibercept’s fusion-protein structure conferring systemic exposure characteristics distinct from antibody-based agents.
Research in ROP has saved infants’ vision, made screening a priority In the 10th and final installment of a series marking OSN’s 25th anniversary, pediatric experts reflect on years of ROP treatment ...
Vision screening has emerged as a salient topic in pediatric ophthalmology in the past year, especially as ophthalmologists face such obstacles as waning industry support and a lack of new technology ...
Trained non-physician evaluators who studied retinal images transmitted to computer screens at a remote central reading center successfully identified newborn infants likely to require a specialized ...
BOULDER, Colo., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Corza Medical, a global medical technology company, today announced that its Ophthalmology business unit has launched the SensorTek™ ROP Kit, the ...
Retinopathy of prematurity (ROP) is one of the most common causes of severe visual impairment and blindness in children worldwide. Because the blood vessels in the retina are not fully developed, ...
The University of Utah's M.E. Hartnett, MD, has a full calendar at this week's Association for Research in Vision and Ophthalmology annual meeting in Orlando. She is organizing and moderating a ...
Premature infants require regular screening for retinopathy of prematurity (ROP), according to an updated policy statement from the American Academy of Pediatrics (AAP). The statement, which was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results